Citations

Clear

1078 citation(s) found for "Gupta, S".

A novel classification of testicular sex cord‐stromal tumours from the Testicular Sex Cord‐Stromal Tumour ( TESST ) group: a collaboration of the Genitourinary Pathology Society (
Acosta, Andrés , Bremmer, Felix , Jc, Cheville, Colecchia, Maurizio , Comperat, Eva, Cornejo, Kristine, Baydar, Dilek E., Gill, A J, Gonzalez‐Peramato, Maria del Pilar, Gupta, Sounak , Hirsch, Michelle S. , Idrees, Muhammad T., Maclean, Fiona, Mohanty, Sambit K., Raspollini, Maria Rosaria , Sangoi, Ankur R , SHOLL, L B, Siegmund, S, Tickoo, Satish K., Tm, Ulbright, Yilmaz, Asli, Sangoi, Ankur R. , Acosta, Andrés M , Matoso, Andres , Menon, Santosh , Michalova, Kvetoslava , Reyes-Mugica, Miguel , Raspollini, Maria Rosaria , Sangoi, Ankur R , Tsuzuki, Toyonori , Berney, Daniel M , Sangoi, Ankur R , Compérat, Éva , Cornejo, Kristine M. , Baydar, Dilek Ertoy , González-Peramato, María Pilar, Idrees, Muhammad T. , Kao, Chia‐Sui , Maclean, Fiona M. , Mehra, Rohit, Mohanty, Sambit K. , Reyes‐Múgica, Miguel , Siegmund, Sophie C., Tickoo, Satish K. , Tsuzuki, Toyonori , Ulbright, Thomas M. , Williamson, Sean R. , Yilmaz, Aslı , Berney, Daniel M.

Mayo Clinic

Histopathology | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/his.70207 | PMID 42421431 Get It

Aims Testicular sex cord‐stromal tumours (TSCSTs) are rare neoplasms that arise from (or show differentiation to) elements derived from the sex cords or intertubular stroma. The current classification (World Health Organization, 2022) is based almost entirely on morphology, with many tumour types such as granulosa cell tumours being defined based on their resemblance to ovarian counterparts. Recent studies have uncovered new clinicopathological, molecular and biological nuances within this group of tumours, underscoring differences with ovarian homologues. Methods and results Considering the new data, a group of genitourinary pathology experts (Testicular Sex Cord‐Stromal Tumour [TESST] group) has proposed a revised ‘TESST classification’ that incorporates the best available evidence. This classification is structured and hierarchical, composed of the following tiers: (1) group, (2) category, (3) entity and (4) histological pattern. ‘Group’ refers to the histological compartment a specific tumour belongs to (sex cords, stroma or both), whereas ‘category’ is defined by the phenotype of the tumour, taking non‐neoplastic elements of the ovary and testis as a reference. The third tier, ‘entity’, refers to neoplasms with shared clinicopathological and/or molecular features that justify classifying them as distinct types. Lastly, ‘histological patterns’ are recurrent morphological variations within entities that are not linked to distinct clinicopathological or molecular features. Conclusions We propose a classification that will provide a framework to improve current clinical management and guide future research in the field.
Are Children with Disabilities Learning When Included in School? a Capability Approach to Participation in the Learning Process in Afghanistan and Pakistan: A Cluster Control Randomised Trial
Trani, Jean‐Francois , Taff, Steven D., Zhu, Yiqi, Bechara, Saria, Raghavan, Ramesh, Gupta, Isheeta, Babulal, Ganesh M., Taff, Steven D. , Bechara, Saria , Raghavan, Ramesh , Kaplan, Ian, Babulal, Ganesh M. , Bakhshi, Parul , Trani, JF

Mayo Clinic

Journal of Human Development and Capabilities | July 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-25

10.1080/19452829.2026.2691737 Get It

Proprioceptive Stimuli as a Trigger for Leucine-Rich Glioma-Inactivated-1 (LGI1) IgG Associated Autoimmune Seizures, a Case Report
Gupta, Ashutosh , Holmes, Miles D., Dubey, Divyanshu, Omidi, Shirin Jamal, Goyal, Megan, Sriwastava, Shitiz, Gupta, Rajesh , Gupta, Ashutosh , Gupta, Rajesh Kumar , Dubey, Divyanshu , Goyal, Megan, Sriwastava, Shitiz

Mayo Clinic

The Neurohospitalist | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/19418744261463745 | PMID 42368480 Get It

Leucine-rich glioma-inactivated-1 (LGI1) IgG-associated autoimmune encephalitis typically presents with faciobrachial dystonic seizures, hyponatremia, and temporal lobe MRI abnormalities. However, the clinical spectrum of LGI1 IgG-associated AE extends beyond these classical features, with reports of diverse seizure semiologies and atypical presentations challenging traditional diagnostic paradigms. This study reports a male in his late 60s presenting with recurrent episodes of right foot cramping and electric shock-like pain, progressing to generalized tonic-clonic seizures. Initial workup suggested chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but LGI1 IgG antibodies were subsequently detected. Despite treatment with intravenous immunoglobulin (IVIG), the seizures persisted. This case highlights the heterogeneity in LGI1 encephalitis presentations. The patient’s proprioceptive-induced reflex seizures represent a rare manifestation of the disease. Treatment with rituximab, a B-cell depleting therapy, resulted in significant improvement, suggesting its potential effectiveness in LGI1 encephalitis with a resistant seizure course. The case also emphasizes the intricate interplay between the mesial temporal lobe, basal ganglia, and frontal regions in LGI1 encephalitis pathophysiology.
A75-15 Pulmonary Involvement (lymphangioleiomyomatosis) In Tuberous Sclerosis Complex (TSC): Analysis Of TSC Alliance Natural History Database
Ussavarungsi, K, Parambil, J G, Gupta, A, Ryu, J H, Ussavarungsi, Kamonpun , Parambil, Joseph G.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 22, 2026 | Volume: 212 | Issue: Supplement_2 | Pages: No page available

10.1093/ajrccm/aamag286.161 Get It

Abstract Background Tuberous sclerosis complex (TSC) is a multisystem genetic disorder frequently associated with lymphangioleiomyomatosis (LAM), a progressive cystic lung disease. The 2022 Updated International TSC Consensus guidelines recommend clinical assessment for LAM and chest CT in all females, and symptomatic males, 18 years or older. We aimed to evaluate pulmonary screening practices along with demographic, genetic and clinical characteristics of those with TSC-LAM in a large national TSC cohort. Methods We conducted a retrospective observational study using the TSC Alliance Natural History Database. Demographic, genetic, and clinical data were extracted. Screening rates for LAM were assessed, and clinical, genetic, and pulmonary characteristics of patients diagnosed with LAM were analyzed. Results Among 2,636 patients with TSC (1,301 females, 49%), molecular testing was performed in 1,591 (60%), identifying TSC1 mutations in 349 (21.9%) and TSC2 mutations in 978 (61.5%). Screening for LAM was reported by 312 patients (11.8%; 42 (13.5%) males), of whom 116 were diagnosed with LAM; 111 (95.7%) were female. Mean age at cohort characterization was 48 years (range 21-80, SD 12.9), and mean age at LAM diagnosis (available in 82 patients) was 33 years (range 14-69, SD 12.5). Among LAM patients, molecular testing was performed in 74 (64%), TSC1 mutations were present in 8 (6.9%), TSC2 in 47 (40.5%), and dual mutations in 2. Common clinical manifestations included renal angiomyolipomas (104, 89.7%), facial angiofibromas (90, 77.6%), epilepsy (70, 60.3%), and subependymal giant cell astrocytoma (27, 23.3%). Pulmonary function data were limited (mean FEV₁ 84.9% predicted, n = 43; mean DLCO 77.6% predicted, n = 27). Serum VEGF-D available in 10 patients, range 331-9,523 pg/mL). Chest CT was performed in 87 patients (75%) and biopsy in 4 (3%). Patient-reported respiratory complications included pneumothorax (14, 12.1%), chylothorax (3, 2.6%), and oxygen requirement (4, 3.4%). Treatments included mTOR inhibitors in 32 (27.6%) and lung transplantation in 1 patient. Conclusion Evaluation for LAM in patients with TSC appears to be underutilized in the U.S. LAM mainly affects women, is linked to TSC2 mutations, and is associated with high rates of renal and dermatologic manifestations. Although guidelines focus on females, LAM can occur in males, highlighting the need for awareness in all TSC patients. Limited lung function and biomarker data reveal gaps in evaluation, with some patients developing severe disease requiring oxygen or lung transplantation. These findings support standardized, genotype-informed surveillance for early detection and targeted care in TSC-related LAM. This abstract is funded by: None
An Annual Review of Important Apheresis Articles in 2025 From the American Society for Apheresis Attending Physician Subcommittee
Zantek, Nicole D. , Lu, Wen , AlMozain, Nour , Lu, Wen , Almozain, Nour , Alsammak, Mohamed , Gupta, Gaurav K , Levenbrown, Yosef , Li, Yanhua , Tripathi, Parmatma Prasad , Tanhehco, Yvette C , Zantek, Nicole D , Dilly, Laura, Martin, Marisa C. Saint, Alsammak, Mohamed , Banez‐Sese, Grace, Chhibber, Vishesh, Costa, Victoria, DeChristopher, Phillip J., Durlen, Ivan , Gupta, Gaurav K. , Li, Yanhua , Mattiazzi, Adela D. , Noland, Daniel K., Prajapati, Vipulkumar, Singh, Nirupama, Siwach, Garima, Wu, Ding Wen , Wehrli, Gay , Tanhehco, Yvette C.

Mayo Clinic

Journal of Clinical Apheresis | June 13, 2026 | Volume: 41 | Issue: 3 | Pages: No page available

10.1002/jca.70142 | PMID 42287024 Get It

ABSTRACT Apheresis medicine is a continually evolving field with numerous studies published each year. To help apheresis practitioners stay up to date with the current literature, members of the American Society for Apheresis (ASFA) Attending Physician Subcommittee identified and summarized 10 seminal articles published in 2025, from the field of apheresis medicine. PubMed was used to identify articles published in four topics including donor apheresis, therapeutic apheresis, apheresis education, and apheresis collection for cellular therapy. These articles met at least one of the following criteria: novel findings, practice‐altering outcomes, international in scope, randomized‐controlled trial, relevant to current clinical practice, and/or provide evidence for category III or IV indications based on the ASFA 9th Special Issue of the Guidelines on the Use of Therapeutic Apheresis in Clinical Practice‐Evidence‐Based Approach. Full length, peer‐reviewed manuscripts in English with data from human subjects were included while case reports, review articles, and meta‐analyses were excluded.
Safety of esophageal endoscopic submucosal dissection of Barrett’s esophageal neoplasia: an analysis of factors associated with stricture formation
Omae, M, Isacsson, N Hentati, Maltzman, H, Mathieu, P, Moll, F, Bourke, M J, Gupta, S, Ebigbo, A, Roser, D A, Deprez, P, Maximilien, B, Wang, K K, Leggett, C L, Koch, A D, Maan, AD I, Baldaque-Silva, F, Omae, Masami , Isacsson, Nils Hentati , Maltzman, Henrik , Moll, Frederic C., Bourke, Michael J. , Ebigbo, Alanna , Barret, Maximilien , Leggett, Cadman L. , Baldaque‐Silva, Francisco

Mayo Clinic

Endoscopy | June 5, 2026 | Volume: 58 | Issue: S 03 | Pages: S107-S108

10.1055/s-0046-1820814 Get It

State of Research in Pediatric Hospital Medicine
Present, Matthew, Ramazani, Suzanne N. , Sauers-Ford, Hadley, Press, V G, Dugani, Sagar B., Gupta, Vineet, Michtalik, Henry J., Rohatgi, Nidhi , McFadden, Vanessa, Pavon, J, Prochaska, Micah, Sauers‐Ford, Hadley S. , Press, Valerie G. , Dugani, Sagar B. , Gupta, Vineet , Pappas, Matthew A. , Michtalik, Henry J. , McFadden, Vanessa , Pavon, Juliessa M. , Prochaska, Micah , Jenkins, Ashley

Mayo Clinic

Hospital Pediatrics | June 5, 2026 | Volume: 16 | Issue: 7 | Pages: e508-e512

10.1542/hpeds.2025-008999 | PMID 42242707 Get It

BACKGROUND/OBJECTIVES Pediatric hospital medicine (PHM) is a growing field with a unique scholarly perspective and evolving role in academic leadership. Since the last systematic assessment of PHM research in 2009, predating subspecialty certification in 2016 and fellowship accreditation in 2020, the research infrastructure within PHM has not been reevaluated. We sought to assess the current state of PHM research by assessing the number, scope, and scholarly domains of research faculty, as well as research funding and support. METHODS Using the Pediatrics Research in Inpatient Settings Network, we distributed a cross-sectional survey to PHM group leaders across the United States and Canada. The 16-item instrument, adapted from prior PHM and adult hospital medicine surveys, assessed program demographics, faculty effort allocation, research support, funding, and scholarly domains. Surveys were distributed via REDCap with follow-up reminders. Descriptive statistics were used. RESULTS 49 programs responded (51% response rate), representing 1702 faculty (∼40% of US pediatric hospitalists). Fewer than half of programs (n = 21, 43%) reported faculty with more than 50% research effort. One-hundred and ninety faculty members (11%) had dedicated research time, and 72% of those conducting quality improvement research did so without any protected effort. Most PHM programs (n = 27, 55%) received less than $100 000 in total annual research funding. CONCLUSIONS Despite recent PHM subspecialty designation and pediatric hospitalist desire to conduct research, dedicated time and associated supports are uncommon in PHM groups. Improvements in the PHM research pipeline will require understanding institutional financial constraints and diversifying and strengthening research funding.
Darier disease—A review highlighting new insights from the Darier Disease International Task Force
Labbouz, Sofia , Xiong, Grace , Murrell, Dedee Frances, Mueller, Simon M. , Mohandesi, Nessa Aghazadeh, Aldhaheri, Ahmed Salem, Asayag, Nissim, Baselga, Eulalia, Nadler, Chen , Chu, Chia‐Yu , Edminister, John R. , Guenova, Emmanuella, Gönülal, Melis , Gostynski, Antoni, Gupta, Lalit Kumar, Mazereeuw‐Hautier, Juliette, Hoetzenecker, Wolfram , Itin, Peter, Jankowski, Marek , Medvecz, Márta, Moosbrugger‐Martinz, Verena , Paller, Amy S., Plázár, Dóra , Queiróz, Amadeu José Rodrigues , Riera‐Monroig, Josep , Rosa, Ralph, Schmuth, Matthias, Freire, Maella Severino , Shabat, Itzhak, Shapiro, Jonathan , Soto‐García, Diego , Stratigos, Alexander J., Tadini, Gianluca Abel, Takeichi, Takuya , Verma, Kaushal K. , Wikström, Jakob D. , Ziv, Michael , Dodiuk‐Gad, Roni Pircha, Xiong, Grace , Mueller, Simon M , Ezzedine, Khaled , Choate, Keith , Gostynski, Antoni , Gupta, Ankan , Hoetzenecker, Wolfram , Jankowski, Marek , Kubo, Akiharu , Lee, Haur Yueh , Lehman, Julia Scott, Mellerio, Jemima E , Queiróz, Amadeu José Rodrigues , Freire, Maella Severino , Shapiro, Jonathan , Soto-García, Diego , Takeichi, Takuya , Wikström, Jakob D , Zink, Alexander , Navarini, Alexander , Hovnanian, Alain , Murrell, D F , Aghazadeh, Nessa , Aldhaheri, Ahmed S., Guenova, Emmanuella , Gönülal, Melis , Mazereeuw‐Hautier, J. , Lehman, Julia S. , Lepekhova, Anfisa A. , Medvecz, Márta, Paller, Amy S. , Schmuth, Matthias , Simpson, Cory L. , Tadini, Gianluca , Wikström, Jakob D. , Dodiuk‐Gad, Roni P.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | June 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jdv.70483 | PMID 42223188 Get It

Abstract Darier disease (DD) is a rare autosomal dominant genodermatosis. This comprehensive review, developed by the Darier Disease International Task Force (DDITF), consolidates current knowledge on the genetic basis, molecular pathophysiology, clinical presentation, diagnosis and management of DD, offering a global perspective that unites shared expertise. The disease arises from pathogenic variants in the ATP2A2 gene, which encodes sarco/endoplasmic reticulum Ca 2+ ‐ATPase isoform 2 (SERCA2), leading to disrupted calcium homeostasis and impaired desmosomal integrity. Clinically, DD is classified based on lesion type (classic vs. non‐classic) and is often accompanied by significant extracutaneous manifestations. Management remains challenging and requires a multifaceted approach, including topical therapies, systemic retinoids and lifestyle modifications. Emerging treatments that target the underlying molecular mechanisms offer promise for improved outcomes. This review aims to provide an updated reference and practical guidance for clinicians involved in the care and study of DD.
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)
Tallantyre, Emma C , Planchon, Sarah M. , Howard, Harriet, Mays, John, Frowd, Nadia, Cohen, Jeffrey A. , Hersh, Carrie M. , Miller, Deborah , Dever, Meredith , Gray, Emma H., LaRocca, Nicholas G., Bale, Clare , Covey-Crump, Gwen, Alvarez, Enrique, Craner, Matt, Freeman, L, Frost, N, Hobart, JC, Hutton, George J, Hyland, Megan , Kalra, S, Kannan, Meena, Kantarci, OH , Lashley, Daniel, Lily, Oliver, Mahad, D, Nicholas, J, Nicholas, R, Paling, David, Pearson, Owen , Rice, Claire M , Samudralwar, Rohini, Schmalstieg, William F., Singh, M, The, E Zune, Zabeti, Aram , Love, Thomas E, Gunzler, Douglas , Liu, Y, GERRY, STEPHEN, Evangelou, N, Hersh, Carrie M , Miller, D M , Nakamura, Kunio , Goldman, Myla D , Harding, Katharine E , Hobart, Jeremy , Kalra, Seema , Nicholas, Richard , Pearson, Owen R , Rice, Claire M , Weinstock‐Guttman, Bianca , Evangelou, Nikos , Ontaneda, Daniel , Cohen, Jeffrey Allen , Tallantyre, Emma Clare , Coles, Alasdair J. , Covey-Crump, Gwen L , Arun, Tarunya , Brownlee, Wallace J , Craner, Matthew J., Freeman, Leorah A. , Goldman, Myla , Gupta, Rajesh , Hutton, George J., Kantarci, Orhun H. , Mahad, Don , Paling, David , The, Ei Zune , Love, Thomas E.

Mayo Clinic

Multiple Sclerosis Journal | May 31, 2026 | Volume: 32 | Issue: 7 | Pages: 722-736

10.1177/13524585261449988 | PMID 42218617 Get It

Background: There is growing support for high-efficacy disease-modifying therapy (DMT) in multiple sclerosis (MS), but escalation (ESC) approaches remain common. Objective: To describe decision-making in a pragmatic trial of early high-efficacy treatment (EHT) versus ESC. Methods: DELIVER-MS is a multi-center, pragmatic, randomized controlled trial (RCT) with a parallel observational study (OBS), which enrolled treatment-naïve people with RRMS in 31 UK/US sites. Primary outcome was as follows: 36-month brain volume loss according to initial treatment approach (EHT vs. ESC). Stepwise multivariable logistic regression was used to predict participation in RCT versus OBS and choice of EHT versus ESC within the OBS cohort. Results: In total, 816 people with MS were enrolled. Participants declined randomization due to preference for a particular DMT (85%), efficacy concerns (20%), and safety concerns (9%). RCT versus OBS participation was associated with lower relapse rate ( p = 0.043) and greater brain parenchymal fraction ( p = 0.002). Among 374 in the OBS cohort, 125 (33%) chose ESC and 249 (67%) chose EHT. People commencing EHT had higher education attainment ( p < 0.001) and relapse rate ( p = 0.025). Conclusion: Baseline DELIVER-MS data demonstrate that participants with milder disease are more likely to participate in RCT. The choice of EHT versus ESC was associated with demographic factors and disease activity. Clinical trial registration: NCT03535298